Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIAS vs Botulinum Toxin for Chronic Anal Fissure
NCT03920449Unknown
- Sponsor
- Mansoura University
- Start
- May 2019
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of botulinum toxin type A in chronic anal fissure (CAF) (2 arms), sponsored by Mansoura University. Primary endpoint: Fissure Healing Rate at 6 months. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
chronic anal fissure (CAF)
Beyond the preview
Go deeper on NCT03920449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03920449.